Learning Objectives

1
(No Transcript)
2
Learning Objectives
3
Variable Response to Clopidogrel
4
Platelet Reactivity and Outcomes
5
Clopidogrel Metabolism
6
CYP450 Genetic Variants and PK/PD
7
CYP2C19 and Clinical Outcomes
8
Clopidogrel Boxed Warning
9
CYP2C19 and Treatment With Clopidogrel
10
CURRENT-OASIS 7 Study Design, Flow, and
Compliance
11
CURRENT-OASIS 7 Clopidogrel Double (600 mg ? 150
mg/d x 7d ? 75 mg/d) vs Standard Dose (300 mg ?
75 mg/d)
12
CURRENT-OASIS 7 Clopidogrel Double- vs
Standard-Dose Bleeding PCI Population
13
Tailoring Clopidogrel Dosing With Platelet
Function Monitoring
14
GRAVITAS Study Design
15
GRAVITAS Primary End Point CV Death, MI, Stent
Thrombosis
16
GRAVITAS Pharmacodynamics Effect of SD vs HD
Clopidogrel
17
PRINCIPLE TIMI 44 PRIMARY EP Acute Phase
18
PRINCIPLE TIMI 44 PRIMARY EP Maintenance Phase
19
TRITON-TIMI 3813,608 Patients With ACS and
Planned PCI Randomized to Prasugrel (60/10) vs
Clopidogrel (300/75)
20
TRITON-TIMI 38 Bleeding Events Safety Cohort (N
13,457)
21
TRILOGY-ACS Study Design
22
TRILOGY-ACS Primary Efficacy End Point to 30
Months (Age lt 75 years)
23
Ticagrelor Pharmacodynamics
24
Platelet Reactivity Ticagrelor vs Prasugrel
25
PLATO Primary Efficacy End Point CV Death, MI,
or Stroke
26
PLATO Bleeding
27
TRA-CER Primary End PointCV Death, MI, Stroke,
Hospitalization for Ischemia, Urgent
Revascularization
28
TRA-CER Bleeding Outcomes
29
CHAMPION PHOENIX Study Design
30
CHAMPION PHOENIX Primary Efficacy Outcomes at 48
Hours, MITT
31
CHAMPION PHOENIX Non-CABG Bleeding at 48 Hours
32
ESC NSTE-ACS Guidelines
33
Periprocedural Antithrombotic Medication in
Primary PCI
34
Antiplatelet Therapy in UA/NSTEMI
35
Antiplatelet Therapy to Support Primary PCI for
STEMI
36
Case 1
37
Case 2
38
Case 3
39
Conclusions
40
Abbreviations
41
Abbreviations (cont)
42
Abbreviations (cont)
43
Abbreviations (cont)
44
References
45
References (cont)
46
References (cont)
47
References (cont)